Debjeet Sur

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Topics

Rheumatoid Arthritis

Hydrogen Peroxide

Disease Activity

Oxidative Stress

Top Venues

Journal of basic and clinical physiology and pharmacology

Immunopharmacology and immunotoxicology

Inflammopharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Oishani Chatterjee, Debjeet Sur
Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat. Journal of basic and clinical physiology and pharmacology 35 (1-2) (2024)
Sourav Mondal, Sarthak Saha, Debjeet Sur
Immuno-metabolic reprogramming of T cell: a new frontier for pharmacotherapy of Rheumatoid arthritis. Immunopharmacology and immunotoxicology 46 (3) (2024)
Sourav Mondal, Sarthak Saha, Debjeet Sur
Immuno-metabolic reprogramming of T cell: a new frontier for pharmacotherapy of Rheumatoid arthritis. Immunopharmacology and immunotoxicology (2024)
Oishani Chatterjee, Debjeet Sur
Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat. Journal of basic and clinical physiology and pharmacology 35 (1-2) (2024)
Sourav Mondal, Sarthak Saha, Debjeet Sur
Immuno-metabolic Reprogramming of T Cell: A New Frontier for Pharmacotherapy of Rheumatoid Arthritis. Immunopharmacology and immunotoxicology (2024)
Oishani Chatterjee, Debjeet Sur
Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat. Journal of basic and clinical physiology and pharmacology (2024)
Oishani Chatterjee, Debjeet Sur
Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat. Journal of basic and clinical physiology and pharmacology 35 (1-2) (2024)
Sourav Mondal, Sarthak Saha, Debjeet Sur
Immuno-metabolic reprogramming of T cell: a new frontier for pharmacotherapy of Rheumatoid arthritis. Immunopharmacology and immunotoxicology 46 (3) (2024)
Debjeet Sur, Chaitali Mondal, Ashok Kumar Balaraman, Pallab Kanti Haldar, Himangshu Sekhar Maji, Asis Bala
Attenuation of COX-2 enzyme by modulating H 2 O 2 -mediated NF-κB signaling pathway by monoamine oxidase inhibitor (MAOI): a further study on the reprofiling of MAOI in acute inflammation. Inflammopharmacology (2023)
Debjeet Sur, Arpan Dutta, Chaitali Mondal, Apurba Banerjee, Pallab Kanti Haldar, Himangshu Sekhar Maji, Asis Bala
Repurposing monoamine oxidase inhibitors (MAOI) for the treatment of rheumatoid arthritis possibly through modulating reactive oxidative stress mediated inflammatory cytokines. Inflammopharmacology 30 (2) (2022)